Navigation Links
According to Surveyed U.S. Oncologists, Zelboraf is the Patient Share Leader in First-Line BRAF-Mutation Positive Malignant Melanoma
Date:11/26/2013

EXTON, Pa., Nov. 26, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, according to oncologists surveyed in Q3 2013, Roche/Genentech/Daiichi Sankyo/Chugai's Zelboraf is the patient share leader in the first-line BRAF-mutation positive setting. Surveyed oncologists also report that Bristol-Myers Squibb's Yervoy holds the most patient share (approximately 50 percent) in the first-line BRAF wild-type setting; Yervoy also captures approximately one-third of patient share in second-line BRAF-mutation positive setting, according to surveyed oncologists. Respondents surveyed in Q3 2013 expect a significant decrease in the first- and second-line patient share of Zelboraf and Yervoy, respectively, within the next six months.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO)

According to the data published in the TreatmentTrends® Malignant Melanoma (US) Q4 2013 report, one-quarter of stage I patients are currently screened for BRAF mutations compared with more than 80 percent of stage IV patients. Medical oncologists expect BRAF screening rates to increase significantly among stage II and stage III patients in the next six months. A small increase in screening among stage IV patients within the next six months suggests that BRAF screening rates may be near saturation point in this subset of patients.

"GlaxoSmithKline's Tafinlar and Mekinist are seeing use as single-agents in BRAF-mutation positive patients, particularly in later lines, following their approval by the FDA in May 2013," said Decision Resources Group Senior Business Insights Analyst Karen Pomeranz, M.Sc., Ph.D. "Interestingly, surveyed respondents indicate that Tafinlar and Mekinist are being used in combination, albeit approximately 5 percent in the first-line BRAF-mutation positive setting, despite the FDA not having recommended use of these agents in combination with one another."

TreatmentTrends® Malignant Melanoma (US) Q4 2013 is a syndicated report designed to provide a view of the current and future management of malignant melanoma based on primary research fielded with 100 medical oncologists in the United States. The report evaluates treatment and diagnosis patterns of the disease and physician opinions on possible future therapy options. BioTrends Oncology is also covering the launch of Tafinlar and Mekinist through its LaunchTrends® studies.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. mHealth market is Expected to Reach $58.8 Billion Globally by 2020 According to Allied Market Research Projections
2. More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists
3. According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
4. In Terms of Effect on Overall Survival, Current and Emerging Therapies Have No Advantage Over Avastin/FOLFIRI in the Treatment of Second-Line Metastatic Colorectal Cancer, According to Clinical Data and Thought Leader Opinion
5. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
6. Annual Healthcare Cost for a Typical American Family is $22,030 According to 2013 Milliman Medical Index
7. Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance
8. Fewer Venture Capital Dollars Invested Into Life Sciences Companies In Q1 2013, According To The MoneyTree Report
9. Food Recalls Driven by Companies Issuing Multiple Recalls in the First Quarter of 2013, According to Latest ExpertRECALL Index
10. Nearly 8 Million Healthcare Personnel Come in Contact with Chemotherapy Drugs, According to CDC
11. Recreational Marijuana Users More Likely To Misuse Prescription Drugs, According to National Study by Quest Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... plc (NASDAQ: ENDP ) will announce its second-quarter 2017 ... management team will host a conference call and webcast before the ... The dial-in number to access the call is U.S./ Canada ... 45397076. Please dial in 10 minutes prior to the scheduled start ... the call will be available from August 8, 2017 at 11:30 ...
(Date:7/13/2017)... July 13, 2017 RK Logistics Group, Inc. was ... certification for its Fremont, CA headquarters ... the Tri-Valley and San Jose for ... of Fremont , with its Fremont Innovation District, is ... such a powerful resource to the hundreds of biotech, pharma ...
(Date:7/12/2017)... Lilly and Company (NYSE: LLY ) has entered ... patent litigation in the U.S. District Court for the Eastern ... ® (tadalafil) unit dose patent. This patent was previously ... the agreement, Cialis exclusivity is now expected to end at ... dose patent for Cialis is valid and infringed by companies ...
Breaking Medicine Technology:
(Date:7/24/2017)... , ... July 24, 2017 , ... A CDC study shows that, although people are ... Caucasians (ages 18 to 29), had at least one case of sunburn within the past ... which causes people to ignore the issue. However, only recently have people become conscientious of ...
(Date:7/24/2017)... ... July 24, 2017 , ... The 2017 NCSL International Workshop ... theme focuses on the new ISO/IEC 17025 standards. This marks the first time ... and calibration will be changed. , As an exhibitor, METTLER TOLEDO will ...
(Date:7/24/2017)... ... July 24, 2017 , ... Paul Vitenas, MD, FACS is excited ... plastic surgeons, invited to attend Allergan’s recent meeting with their Plastics Advisory Board. As ... the world, Allergan is bringing a newly defined structure to the aesthetics market. ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... CURE announced that they have enrolled over 100,000 children in their treatment program. ... born every year in areas where treatment is limited or non-existent. Without intervention, ...
(Date:7/24/2017)... Church, VA (PRWEB) , ... July 24, 2017 ... ... figuring out how to change manufacturers future. , The agency is hammering out ... Cures Act, one of the farthest-ranging laws ever to affect FDA-regulated firms. The ...
Breaking Medicine News(10 mins):